Abstract
LKB1 (also known as serine-threonine kinase 11, STK11) is a tumor suppressor, which is mutated or deleted in Peutz-Jeghers syndrome (PJS) and in a variety of cancers. Physiologically, LKB1 possesses multiple cellular functions in the regulation of cell bioenergetics metabolism, cell cycle arrest, embryo development, cell polarity, and apoptosis. New studies demonstrated that LKB1 may also play a role in the maintenance of function and dynamics of hematopoietic stem cells. Over the past years, personalized therapy targeting specific genetic aberrations has attracted intense interests. Within this review, several agents with potential activity against aberrant LKB1 signaling have been discussed. Potential strategies and challenges in targeting LKB1 inactivation are also considered.
Keywords: LKB1 (serine-threonine kinase 11, STK11), AMP-activated protein kinase (AMPK), tumor suppression, mutations, targeting therapeutics.
Current Drug Targets
Title:Targeting the LKB1 Tumor Suppressor
Volume: 15 Issue: 1
Author(s): Rui-Xun Zhao and Zhi-Xiang Xu
Affiliation:
Keywords: LKB1 (serine-threonine kinase 11, STK11), AMP-activated protein kinase (AMPK), tumor suppression, mutations, targeting therapeutics.
Abstract: LKB1 (also known as serine-threonine kinase 11, STK11) is a tumor suppressor, which is mutated or deleted in Peutz-Jeghers syndrome (PJS) and in a variety of cancers. Physiologically, LKB1 possesses multiple cellular functions in the regulation of cell bioenergetics metabolism, cell cycle arrest, embryo development, cell polarity, and apoptosis. New studies demonstrated that LKB1 may also play a role in the maintenance of function and dynamics of hematopoietic stem cells. Over the past years, personalized therapy targeting specific genetic aberrations has attracted intense interests. Within this review, several agents with potential activity against aberrant LKB1 signaling have been discussed. Potential strategies and challenges in targeting LKB1 inactivation are also considered.
Export Options
About this article
Cite this article as:
Zhao Rui-Xun and Xu Zhi-Xiang, Targeting the LKB1 Tumor Suppressor, Current Drug Targets 2014; 15 (1) . https://dx.doi.org/10.2174/1389450114666140106095811
DOI https://dx.doi.org/10.2174/1389450114666140106095811 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets Prevalence of Dietary Supplement use and its Relation to Maternal Characteristics in Iranian Pregnant Women
Current Women`s Health Reviews The Role of Fibroblast Growth Factor 21 (FGF21) on Energy Balance, Glucose and Lipid Metabolism
Current Diabetes Reviews Nurse-led and Interdisciplinary Secondary Cardiovascular Prevention Programmes: Spanish Cohort of the EUROACTION Project
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Glycemic Control is Related to Cognitive Dysfunction in Elderly People with Type 2 Diabetes Mellitus in a Rural Chinese Population
Current Alzheimer Research Ghrelin Receptor Signaling: A Promising Therapeutic Target for Metabolic Syndrome and Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic: Sepsis Pathogenesis: How Many Pieces are There in the Puzzle? (Guest Editor: Luciano Cesar Pontes Azevedo)]
Endocrine, Metabolic & Immune Disorders - Drug Targets LCHAD and MTP Deficiencies - Two Disorders of Mitochondrial Fatty Acid β-Oxidation with Unusual Features
Current Pediatric Reviews Search for Potential Inducible Nitric Oxide Synthase Inhibitors with Favorable ADMET Profiles for the Therapy of Helicobacter pylori Infections
Current Topics in Medicinal Chemistry Stem Cells Therapies in Basic Science and Translational Medicine: Current Status and Treatment Monitoring Strategies
Current Pharmaceutical Biotechnology Biologic Agents for Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Chromogranin A (CgA) in Monitoring Patients with Prostate Cancer Under Androgen Deprivation Therapy: Comparison with Prostatic Specific Antigen (PSA)
Current Radiopharmaceuticals PPARγ Agonistic Activity of Sulphonylureas
Endocrine, Metabolic & Immune Disorders - Drug Targets Medullary Thyroid Cancer with Paraganglioma-Like Pattern Diagnosed During Pregnancy: A Case Report and Literature Revision
Endocrine, Metabolic & Immune Disorders - Drug Targets Optical Imaging Agents and Potential Application in the Assessment of Pancreatic Beta Cells
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Seaweed Extract Improves Carbohydrate Metabolism in Overweight and Obese Adults
Current Nutrition & Food Science Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review
Current Pharmaceutical Design Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer
Current Medicinal Chemistry Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment
Current Pharmaceutical Design